Welcome to our dedicated page for Immix Biopharma news (Ticker: IMMX), a resource for investors and traders seeking the latest updates and insights on Immix Biopharma stock.
Immix Biopharma, Inc. develops clinical-stage cell therapies focused on relapsed/refractory AL Amyloidosis, led by NXC-201, a sterically optimized BCMA-targeted CAR-T therapy. Company news commonly covers NXC-201 clinical data from the NEXICART-2 study, FDA designations such as Breakthrough Therapy, RMAT and orphan-drug status, and regulatory-development planning.
Updates also include equity financings, pre-funded warrants, private placements, investor-conference participation, and commercial and medical leadership additions tied to the company’s rare-disease oncology and hematology strategy.
Immix Biopharma (NASDAQ:IMMX) reported positive Phase 2 results for NXC-201 at ASH 2025 with an independent review committee complete response (CR) rate of 75% (15/20) at s/u IFE(-).
MRD negativity in bone marrow was observed in 4 of 5 pending patients, which the company says could raise the CR to 95%. Downstream organ responses occurred in 70% of evaluable patients (7/10). No neurotoxicity and only low-grade cytokine release syndrome (median duration 1 day) were reported. NEXICART-2 final readout and planned BLA submission in 2026. Data cutoff: Nov 13, 2025.
Immix Biopharma (NASDAQ:IMMX) appointed Michael Grabow as Chief Commercial Officer effective Nov 12, 2025 to lead U.S. commercialization and launch of NXC-201 in relapsed/refractory AL amyloidosis. The company highlighted Michael’s >25 years of commercialization experience and his role leading MODEYSO® go-to-market at Chimerix, which was acquired by Jazz for $935 million in 2025. Immix noted NXC-201 has received RMAT and Orphan Drug Designation from the FDA and positions a one-and-done approach for a disease with no currently approved FDA therapies.
Immix Biopharma (NASDAQ: IMMX) announced that interim Phase 1/2 results from its U.S. NXC-201 NEXICART-2 trial in relapsed/refractory AL amyloidosis were selected for an oral presentation at ASH 2025.
The oral presentation is scheduled for December 7, 2025, 5:45–6:00 PM ET (Abstract abs25-14730) in Session 652: MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias. The presentation covers first 20-patient safety and efficacy data from NEXICART-2, described as the first U.S. CAR-T trial in relapsed/refractory light-chain (AL) amyloidosis. Event details are available on Immix Biopharma’s investor presentations page.
Immix Biopharma (NASDAQ: IMMX) will present and host institutional investor meetings at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, MA, November 10-12, 2025.
Management will participate in a Fireside Chat on November 11, 2025 at 12:30 PM ET and will be available for one-on-one meetings by request through Guggenheim representatives. A replay link will be posted on the company’s Investors > Presentation & Events page when available.
Immix Biopharma (NASDAQ:IMMX) will present an abstract for NXC-201 at the American Society of Hematology 67th Annual Meeting, December 6-9, 2025, in Orlando, Florida. The company, focused on relapsed/refractory AL amyloidosis, announced participation and an abstract presentation slot at the conference.
Immix Biopharma (NASDAQ:IMMX), a clinical-stage biopharmaceutical company focused on developing cell therapies for AL Amyloidosis and other serious diseases, has announced its participation in the 37th Annual Piper Sandler Healthcare Conference.
The conference will take place on December 2-4, 2025 at the Lotte New York Palace Hotel in New York. The company will conduct institutional investor meetings and interested investors can arrange one-on-one meetings through their Piper Sandler representative. A replay of the presentation will be available on the company's website under the Investors section.
Immix Biopharma (NASDAQ:IMMX) has announced surpassing the 50% enrollment milestone in its NEXICART-2 clinical trial, evaluating NXC-201, a sterically-optimized CAR-T therapy for relapsed/refractory AL Amyloidosis.
The company is advancing toward its goal of achieving the first FDA-approved cell therapy Biologics License Application (BLA) for this orphan indication, where currently no FDA-approved treatments exist. The trial's interim results were presented at ASCO 2025 by Dr. Heather Landau of Memorial Sloan Kettering Cancer Center, with growing interest from clinicians and patients following the presentation.
Immix Biopharma (NASDAQ:IMMX), a clinical-stage biopharmaceutical company, has appointed Dr. Nancy T. Chang to its Board of Directors. Dr. Chang, former CEO of Tanox Inc., joins concurrent with her investment through Goose Capital.
Dr. Chang brings significant expertise, having led the development of several successful drugs including XOLAIR® for severe asthma, TROGARZO® for HIV, and EBGLYSS® for dermatitis. These drugs have collectively generated over $5 billion in sales. Notably, under her leadership, Tanox was acquired by Genentech/Roche for $919 million.
Immix Biopharma (NASDAQ:IMMX), a clinical-stage biopharmaceutical company, has secured a strategic investment from Goose Capital, led by former Tanox CEO Dr. Nancy T. Chang. Dr. Chang's track record includes developing successful FDA-approved drugs like XOLAIR®, TROGARZO®, and EBGLYSS®, which have collectively generated over $5 billion in sales.
The investment aims to support Immix's development of cell therapies for AL Amyloidosis and other serious diseases, particularly the commercialization of NXC-201 for relapsed/refractory AL Amyloidosis. This strategic partnership brings valuable expertise to Immix, as Dr. Chang has significant experience in bringing drugs from invention through FDA approval and commercialization.
Immix Biopharma (NASDAQ:IMMX), a clinical-stage biopharmaceutical company focused on developing cell therapies for AL Amyloidosis and other serious diseases, has announced its participation in the upcoming Stifel 2025 Healthcare Conference.
The conference will take place from November 11-13, 2025 at the Lotte New York Palace Hotel in New York. The company will conduct institutional investor meetings and one-on-one sessions during the event. Interested investors can arrange meetings through their Stifel representatives. A replay of the presentation will be available on the company's website under the Investors section.